APO Research
Talk to an analyst

APO RESEARCH · REPORT

T Cell Antigen Gp39

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global T Cell Antigen Gp39 Market Outlook and Growth Opportunities 2026

19 December 2025191 pages

Choose your research edition.

Industry ResearchT Cell Antigen Gp39 Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal T Cell Antigen Gp39 Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal T Cell Antigen Gp39 Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032181 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal T Cell Antigen Gp39 Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal T Cell Antigen Gp39 Market Analysis and Forecast 2026-2032198 pages · $4,950 USD

Market perspective

The global T Cell Antigen Gp39 market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for T Cell Antigen Gp39 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for T Cell Antigen Gp39 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for T Cell Antigen Gp39 is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the T Cell Antigen Gp39 market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the T Cell Antigen Gp39 market include Biogen, Inc., XL-protein GmbH, Targovax AS, MedImmune, LLC, Juno Therapeutics Inc., ImmuNext, Inc., eTheRNA Immunotherapies NV and Bristol-Myers Squibb Company, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global T Cell Antigen Gp39 market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of T Cell Antigen Gp39 and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents T Cell Antigen Gp39 sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the T Cell Antigen Gp39 market size, projected growth trends, production technologies, key applications, and end-use industries.

T Cell Antigen Gp39 Segment by Company

Biogen, Inc.

XL-protein GmbH

Targovax AS

MedImmune, LLC

Juno Therapeutics Inc.

ImmuNext, Inc.

eTheRNA Immunotherapies NV

Bristol-Myers Squibb Company

T Cell Antigen Gp39 Segment by Type

ECI-006

Hepatitis B Vaccine

ISF-35

INX-021

Others

T Cell Antigen Gp39 Segment by Application

Graft Versus Host Disease

Panceratic Cancer

Breast Cancer

Bladder Cancer

Others

T Cell Antigen Gp39 Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global T Cell Antigen Gp39 status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions T Cell Antigen Gp39 market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify T Cell Antigen Gp39 significant trends, drivers, influence factors in global and regions.

6. To analyze T Cell Antigen Gp39 competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global T Cell Antigen Gp39 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of T Cell Antigen Gp39 and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of T Cell Antigen Gp39.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the T Cell Antigen Gp39 market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global T Cell Antigen Gp39 industry.

Chapter 3: Detailed analysis of T Cell Antigen Gp39 manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of T Cell Antigen Gp39 in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of T Cell Antigen Gp39 in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. T Cell Antigen Gp39 Industry Trends Table 2. T Cell Antigen Gp39 Industry Drivers Table 3. T Cell Antigen Gp39 Industry Opportunities and Challenges Table 4. T Cell Antigen Gp39 Industry Restraints Table 5. Global T Cell Antigen Gp39 Revenue by Company (US$ Million) & (2021-2026) Table 6. Global T Cell Antigen Gp39 Revenue Share by Company (2021-2026) Table 7. Global T Cell Antigen Gp39 Sales Volume by Company (K Units) & (2021-2026) Table 8. Global T Cell Antigen Gp39 Sales Volume Share by Company (2021-2026) Table 9. Global T Cell Antigen Gp39 Average Price (US$/Unit) of Company (2021-2026) Table 10. Global T Cell Antigen Gp39 Company Ranking, (2024-2026) & (USD Million) Table 11. Global T Cell Antigen Gp39 Key Company Manufacturing Base & Headquarters Table 12. Global T Cell Antigen Gp39 Company, Product Type & Application Table 13. Global T Cell Antigen Gp39 Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global T Cell Antigen Gp39 by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of ECI-006 Table 18. Significant Companies of Hepatitis B Vaccine Table 19. Significant Companies of ISF-35 Table 20. Significant Companies of INX-021 Table 21. Significant Companies of Others Table 22. Global T Cell Antigen Gp39 Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 23. Global T Cell Antigen Gp39 Sales Volume by Type (2021-2026) & (K Units) Table 24. Global T Cell Antigen Gp39 Sales Volume by Type (2027-2032) & (K Units) Table 25. Global T Cell Antigen Gp39 Sales Volume Share by Type (2021-2026) Table 26. Global T Cell Antigen Gp39 Sales Volume Share by Type (2027-2032) Table 27. Global T Cell Antigen Gp39 Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global T Cell Antigen Gp39 Sales Value by Type (2021-2026) & (US$ Million) Table 29. Global T Cell Antigen Gp39 Sales Value by Type (2027-2032) & (US$ Million) Table 30. Global T Cell Antigen Gp39 Sales Value Share by Type (2021-2026) Table 31. Global T Cell Antigen Gp39 Sales Value Share by Type (2027-2032) Table 32. Significant Companies of Graft Versus Host Disease Table 33. Significant Companies of Panceratic Cancer Table 34. Significant Companies of Breast Cancer Table 35. Significant Companies of Bladder Cancer Table 36. Significant Companies of Others Table 37. Global T Cell Antigen Gp39 Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 38. Global T Cell Antigen Gp39 Sales Volume by Application (2021-2026) & (K Units) Table 39. Global T Cell Antigen Gp39 Sales Volume by Application (2027-2032) & (K Units) Table 40. Global T Cell Antigen Gp39 Sales Volume Share by Application (2021-2026) Table 41. Global T Cell Antigen Gp39 Sales Volume Share by Application (2027-2032) Table 42. Global T Cell Antigen Gp39 Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 43. Global T Cell Antigen Gp39 Sales Value by Application (2021-2026) & (US$ Million) Table 44. Global T Cell Antigen Gp39 Sales Value by Application (2027-2032) & (US$ Million) Table 45. Global T Cell Antigen Gp39 Sales Value Share by Application (2021-2026) Table 46. Global T Cell Antigen Gp39 Sales Value Share by Application (2027-2032) Table 47. Global T Cell Antigen Gp39 Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 48. Global T Cell Antigen Gp39 Sales by Region (2021-2026) & (K Units) Table 49. Global T Cell Antigen Gp39 Sales Market Share by Region (2021-2026) Table 50. Global T Cell Antigen Gp39 Sales by Region (2027-2032) & (K Units) Table 51. Global T Cell Antigen Gp39 Sales Market Share by Region (2027-2032) Table 52. Global T Cell Antigen Gp39 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 53. Global T Cell Antigen Gp39 Sales Value by Region (2021-2026) & (US$ Million) Table 54. Global T Cell Antigen Gp39 Sales Value Share by Region (2021-2026) Table 55. Global T Cell Antigen Gp39 Sales Value by Region (2027-2032) & (US$ Million) Table 56. Global T Cell Antigen Gp39 Sales Value Share by Region (2027-2032) Table 57. Global T Cell Antigen Gp39 Market Average Price (US$/Unit) by Region (2021-2026) Table 58. Global T Cell Antigen Gp39 Market Average Price (US$/Unit) by Region (2027-2032) Table 59. Global T Cell Antigen Gp39 Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 60. Global T Cell Antigen Gp39 Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global T Cell Antigen Gp39 Sales by Country (2021-2026) & (K Units) Table 62. Global T Cell Antigen Gp39 Sales Market Share by Country (2021-2026) Table 63. Global T Cell Antigen Gp39 Sales by Country (2027-2032) & (K Units) Table 64. Global T Cell Antigen Gp39 Sales Market Share by Country (2027-2032) Table 65. Global T Cell Antigen Gp39 Sales Value by Country (2021-2026) & (US$ Million) Table 66. Global T Cell Antigen Gp39 Sales Value Market Share by Country (2021-2026) Table 67. Global T Cell Antigen Gp39 Sales Value by Country (2027-2032) & (US$ Million) Table 68. Global T Cell Antigen Gp39 Sales Value Market Share by Country (2027-2032) Table 69. Biogen, Inc. Company Information Table 70. Biogen, Inc. Business Overview Table 71. Biogen, Inc. T Cell Antigen Gp39 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Biogen, Inc. T Cell Antigen Gp39 Product Portfolio Table 73. Biogen, Inc. Recent Development Table 74. XL-protein GmbH Company Information Table 75. XL-protein GmbH Business Overview Table 76. XL-protein GmbH T Cell Antigen Gp39 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. XL-protein GmbH T Cell Antigen Gp39 Product Portfolio Table 78. XL-protein GmbH Recent Development Table 79. Targovax AS Company Information Table 80. Targovax AS Business Overview Table 81. Targovax AS T Cell Antigen Gp39 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Targovax AS T Cell Antigen Gp39 Product Portfolio Table 83. Targovax AS Recent Development Table 84. MedImmune, LLC Company Information Table 85. MedImmune, LLC Business Overview Table 86. MedImmune, LLC T Cell Antigen Gp39 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. MedImmune, LLC T Cell Antigen Gp39 Product Portfolio Table 88. MedImmune, LLC Recent Development Table 89. Juno Therapeutics Inc. Company Information Table 90. Juno Therapeutics Inc. Business Overview Table 91. Juno Therapeutics Inc. T Cell Antigen Gp39 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Juno Therapeutics Inc. T Cell Antigen Gp39 Product Portfolio Table 93. Juno Therapeutics Inc. Recent Development Table 94. ImmuNext, Inc. Company Information Table 95. ImmuNext, Inc. Business Overview Table 96. ImmuNext, Inc. T Cell Antigen Gp39 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. ImmuNext, Inc. T Cell Antigen Gp39 Product Portfolio Table 98. ImmuNext, Inc. Recent Development Table 99. eTheRNA Immunotherapies NV Company Information Table 100. eTheRNA Immunotherapies NV Business Overview Table 101. eTheRNA Immunotherapies NV T Cell Antigen Gp39 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. eTheRNA Immunotherapies NV T Cell Antigen Gp39 Product Portfolio Table 103. eTheRNA Immunotherapies NV Recent Development Table 104. Bristol-Myers Squibb Company Company Information Table 105. Bristol-Myers Squibb Company Business Overview Table 106. Bristol-Myers Squibb Company T Cell Antigen Gp39 Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Bristol-Myers Squibb Company T Cell Antigen Gp39 Product Portfolio Table 108. Bristol-Myers Squibb Company Recent Development Table 109. Key Raw Materials Table 110. Raw Materials Key Suppliers Table 111. T Cell Antigen Gp39 Distributors List Table 112. T Cell Antigen Gp39 Customers List Table 113. Research Programs/Design for This Report Table 114. Authors List of This Report Table 115. Secondary Sources Table 116. Primary Sources List of Figures Figure 1. T Cell Antigen Gp39 Product Image Figure 2. Global T Cell Antigen Gp39 Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global T Cell Antigen Gp39 Sales Value (2021-2032) & (US$ Million) Figure 4. Global T Cell Antigen Gp39 Sales (2021-2032) & (K Units) Figure 5. Global T Cell Antigen Gp39 Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global T Cell Antigen Gp39 Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. ECI-006 Image Figure 10. Hepatitis B Vaccine Image Figure 11. ISF-35 Image Figure 12. INX-021 Image Figure 13. Others Image Figure 14. Global T Cell Antigen Gp39 Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 15. Global T Cell Antigen Gp39 Sales Volume Share 2021 VS 2025 VS 2032 Figure 16. Global T Cell Antigen Gp39 Sales Volume Share by Type (2021-2032) Figure 17. Global T Cell Antigen Gp39 Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global T Cell Antigen Gp39 Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global T Cell Antigen Gp39 Sales Value Share by Type (2021-2032) Figure 20. Graft Versus Host Disease Image Figure 21. Panceratic Cancer Image Figure 22. Breast Cancer Image Figure 23. Bladder Cancer Image Figure 24. Others Image Figure 25. Global T Cell Antigen Gp39 Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global T Cell Antigen Gp39 Sales Volume Share 2021 VS 2025 VS 2032 Figure 27. Global T Cell Antigen Gp39 Sales Volume Share by Application (2021-2032) Figure 28. Global T Cell Antigen Gp39 Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 29. Global T Cell Antigen Gp39 Sales Value Share 2021 VS 2025 VS 2032 Figure 30. Global T Cell Antigen Gp39 Sales Value Share by Application (2021-2032) Figure 31. Global T Cell Antigen Gp39 Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 32. Global T Cell Antigen Gp39 Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 33. Global T Cell Antigen Gp39 Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 34. Global T Cell Antigen Gp39 Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 35. North America T Cell Antigen Gp39 Sales Value (2021-2032) & (US$ Million) Figure 36. North America T Cell Antigen Gp39 Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Europe T Cell Antigen Gp39 Sales Value (2021-2032) & (US$ Million) Figure 38. Europe T Cell Antigen Gp39 Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Asia-Pacific T Cell Antigen Gp39 Sales Value (2021-2032) & (US$ Million) Figure 40. Asia-Pacific T Cell Antigen Gp39 Sales Value Share by Country (%), 2025 VS 2032 Figure 41. South America T Cell Antigen Gp39 Sales Value (2021-2032) & (US$ Million) Figure 42. South America T Cell Antigen Gp39 Sales Value Share by Country (%), 2025 VS 2032 Figure 43. Middle East & Africa T Cell Antigen Gp39 Sales Value (2021-2032) & (US$ Million) Figure 44. Middle East & Africa T Cell Antigen Gp39 Sales Value Share by Country (%), 2025 VS 2032 Figure 45. USA T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. USA T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. USA T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Canada T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Canada T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Canada T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Mexico T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Mexico T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Mexico T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Germany T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Germany T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Germany T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. France T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. France T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. France T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. U.K. T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. U.K. T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. U.K. T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Italy T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Italy T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Italy T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Spain T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Spain T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Spain T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Russia T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Russia T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Russia T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. Netherlands T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. Netherlands T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. Netherlands T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Nordic Countries T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Nordic Countries T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Nordic Countries T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. China T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. China T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. China T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Japan T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Japan T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Japan T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. South Korea T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. South Korea T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. South Korea T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. India T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. India T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. India T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Australia T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Australia T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Australia T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Southeast Asia T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Southeast Asia T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Southeast Asia T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Brazil T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Brazil T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Brazil T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Argentina T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Argentina T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Argentina T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Chile T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Chile T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Chile T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Colombia T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Colombia T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Colombia T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Peru T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Peru T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Peru T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Saudi Arabia T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Saudi Arabia T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Saudi Arabia T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Israel T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Israel Arabia T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Israel Arabia T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. UAE T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. UAE T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. UAE T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Turkey T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Turkey T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Turkey T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Iran T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 124. Iran T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 125. Iran T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 126. Egypt T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 127. Egypt T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032 & (%) Figure 128. Egypt T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032 & (%) Figure 129. T Cell Antigen Gp39 Value Chain Figure 130. Manufacturing Cost Structure Figure 131. T Cell Antigen Gp39 Sales Mode & Process Figure 132. Direct Comparison with Distribution Share Figure 133. Distributors Profiles Figure 134. Years Considered Figure 135. Research Process Figure 136. Key Executives Interviewed

Scope & coverage.

Types
  • ECI-006
  • Hepatitis B Vaccine
  • ISF-35
  • INX-021
  • Others
Applications
  • Graft Versus Host Disease
  • Panceratic Cancer
  • Breast Cancer
  • Bladder Cancer
  • Others
Companies covered
  • Biogen, Inc.
  • XL-protein GmbH
  • Targovax AS
  • MedImmune, LLC
  • Juno Therapeutics Inc.
  • ImmuNext, Inc.
  • eTheRNA Immunotherapies NV
  • Bristol-Myers Squibb Company

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global T Cell Antigen Gp39 Sales Value (2021-2032)
  4. 1.2.2 Global T Cell Antigen Gp39 Sales Volume (2021-2032)
  5. 1.2.3 Global T Cell Antigen Gp39 Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 T Cell Antigen Gp39 Market Dynamics
  1. 2.1 T Cell Antigen Gp39 Industry Trends
  2. 2.2 T Cell Antigen Gp39 Industry Drivers
  3. 2.3 T Cell Antigen Gp39 Industry Opportunities and Challenges
  4. 2.4 T Cell Antigen Gp39 Industry Restraints
3 T Cell Antigen Gp39 Market by Company
  1. 3.1 Global T Cell Antigen Gp39 Company Revenue Ranking in 2025
  2. 3.2 Global T Cell Antigen Gp39 Revenue by Company (2021-2026)
  3. 3.3 Global T Cell Antigen Gp39 Sales Volume by Company (2021-2026)
  4. 3.4 Global T Cell Antigen Gp39 Average Price by Company (2021-2026)
  5. 3.5 Global T Cell Antigen Gp39 Company Ranking (2024-2026)
  6. 3.6 Global T Cell Antigen Gp39 Company Manufacturing Base and Headquarters
  7. 3.7 Global T Cell Antigen Gp39 Company Product Type and Application
  8. 3.8 Global T Cell Antigen Gp39 Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global T Cell Antigen Gp39 Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 T Cell Antigen Gp39 Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 T Cell Antigen Gp39 Market by Type
  1. 4.1 T Cell Antigen Gp39 Type Introduction
  2. 4.1.1 ECI-006
  3. 4.1.2 Hepatitis B Vaccine
  4. 4.1.3 ISF-35
  5. 4.1.4 INX-021
  6. 4.1.5 Others
  7. 4.2 Global T Cell Antigen Gp39 Sales Volume by Type
  8. 4.2.1 Global T Cell Antigen Gp39 Sales Volume by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global T Cell Antigen Gp39 Sales Volume by Type (2021-2032)
  10. 4.2.3 Global T Cell Antigen Gp39 Sales Volume Share by Type (2021-2032)
  11. 4.3 Global T Cell Antigen Gp39 Sales Value by Type
  12. 4.3.1 Global T Cell Antigen Gp39 Sales Value by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global T Cell Antigen Gp39 Sales Value by Type (2021-2032)
  14. 4.3.3 Global T Cell Antigen Gp39 Sales Value Share by Type (2021-2032)
5 T Cell Antigen Gp39 Market by Application
  1. 5.1 T Cell Antigen Gp39 Application Introduction
  2. 5.1.1 Graft Versus Host Disease
  3. 5.1.2 Panceratic Cancer
  4. 5.1.3 Breast Cancer
  5. 5.1.4 Bladder Cancer
  6. 5.1.5 Others
  7. 5.2 Global T Cell Antigen Gp39 Sales Volume by Application
  8. 5.2.1 Global T Cell Antigen Gp39 Sales Volume by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global T Cell Antigen Gp39 Sales Volume by Application (2021-2032)
  10. 5.2.3 Global T Cell Antigen Gp39 Sales Volume Share by Application (2021-2032)
  11. 5.3 Global T Cell Antigen Gp39 Sales Value by Application
  12. 5.3.1 Global T Cell Antigen Gp39 Sales Value by Application (2021 VS 2025 VS 2032)
  13. 5.3.2 Global T Cell Antigen Gp39 Sales Value by Application (2021-2032)
  14. 5.3.3 Global T Cell Antigen Gp39 Sales Value Share by Application (2021-2032)
6 T Cell Antigen Gp39 Regional Sales and Value Analysis
  1. 6.1 Global T Cell Antigen Gp39 Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global T Cell Antigen Gp39 Sales by Region (2021-2032)
  3. 6.2.1 Global T Cell Antigen Gp39 Sales by Region: 2021-2026
  4. 6.2.2 Global T Cell Antigen Gp39 Sales by Region (2027-2032)
  5. 6.3 Global T Cell Antigen Gp39 Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global T Cell Antigen Gp39 Sales Value by Region (2021-2032)
  7. 6.4.1 Global T Cell Antigen Gp39 Sales Value by Region: 2021-2026
  8. 6.4.2 Global T Cell Antigen Gp39 Sales Value by Region (2027-2032)
  9. 6.5 Global T Cell Antigen Gp39 Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America T Cell Antigen Gp39 Sales Value (2021-2032)
  12. 6.6.2 North America T Cell Antigen Gp39 Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe T Cell Antigen Gp39 Sales Value (2021-2032)
  15. 6.7.2 Europe T Cell Antigen Gp39 Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific T Cell Antigen Gp39 Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific T Cell Antigen Gp39 Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America T Cell Antigen Gp39 Sales Value (2021-2032)
  21. 6.9.2 South America T Cell Antigen Gp39 Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa T Cell Antigen Gp39 Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa T Cell Antigen Gp39 Sales Value Share by Country, 2025 VS 2032
7 T Cell Antigen Gp39 Country-level Sales and Value Analysis
  1. 7.1 Global T Cell Antigen Gp39 Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global T Cell Antigen Gp39 Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global T Cell Antigen Gp39 Sales by Country (2021-2032)
  4. 7.3.1 Global T Cell Antigen Gp39 Sales by Country (2021-2026)
  5. 7.3.2 Global T Cell Antigen Gp39 Sales by Country (2027-2032)
  6. 7.4 Global T Cell Antigen Gp39 Sales Value by Country (2021-2032)
  7. 7.4.1 Global T Cell Antigen Gp39 Sales Value by Country (2021-2026)
  8. 7.4.2 Global T Cell Antigen Gp39 Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt T Cell Antigen Gp39 Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt T Cell Antigen Gp39 Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt T Cell Antigen Gp39 Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Biogen, Inc.
  2. 8.1.1 Biogen, Inc. Company Information
  3. 8.1.2 Biogen, Inc. Business Overview
  4. 8.1.3 Biogen, Inc. T Cell Antigen Gp39 Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Biogen, Inc. T Cell Antigen Gp39 Product Portfolio
  6. 8.1.5 Biogen, Inc. Recent Developments
  7. 8.2 XL-protein GmbH
  8. 8.2.1 XL-protein GmbH Company Information
  9. 8.2.2 XL-protein GmbH Business Overview
  10. 8.2.3 XL-protein GmbH T Cell Antigen Gp39 Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 XL-protein GmbH T Cell Antigen Gp39 Product Portfolio
  12. 8.2.5 XL-protein GmbH Recent Developments
  13. 8.3 Targovax AS
  14. 8.3.1 Targovax AS Company Information
  15. 8.3.2 Targovax AS Business Overview
  16. 8.3.3 Targovax AS T Cell Antigen Gp39 Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Targovax AS T Cell Antigen Gp39 Product Portfolio
  18. 8.3.5 Targovax AS Recent Developments
  19. 8.4 MedImmune, LLC
  20. 8.4.1 MedImmune, LLC Company Information
  21. 8.4.2 MedImmune, LLC Business Overview
  22. 8.4.3 MedImmune, LLC T Cell Antigen Gp39 Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 MedImmune, LLC T Cell Antigen Gp39 Product Portfolio
  24. 8.4.5 MedImmune, LLC Recent Developments
  25. 8.5 Juno Therapeutics Inc.
  26. 8.5.1 Juno Therapeutics Inc. Company Information
  27. 8.5.2 Juno Therapeutics Inc. Business Overview
  28. 8.5.3 Juno Therapeutics Inc. T Cell Antigen Gp39 Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Juno Therapeutics Inc. T Cell Antigen Gp39 Product Portfolio
  30. 8.5.5 Juno Therapeutics Inc. Recent Developments
  31. 8.6 ImmuNext, Inc.
  32. 8.6.1 ImmuNext, Inc. Company Information
  33. 8.6.2 ImmuNext, Inc. Business Overview
  34. 8.6.3 ImmuNext, Inc. T Cell Antigen Gp39 Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 ImmuNext, Inc. T Cell Antigen Gp39 Product Portfolio
  36. 8.6.5 ImmuNext, Inc. Recent Developments
  37. 8.7 eTheRNA Immunotherapies NV
  38. 8.7.1 eTheRNA Immunotherapies NV Company Information
  39. 8.7.2 eTheRNA Immunotherapies NV Business Overview
  40. 8.7.3 eTheRNA Immunotherapies NV T Cell Antigen Gp39 Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 eTheRNA Immunotherapies NV T Cell Antigen Gp39 Product Portfolio
  42. 8.7.5 eTheRNA Immunotherapies NV Recent Developments
  43. 8.8 Bristol-Myers Squibb Company
  44. 8.8.1 Bristol-Myers Squibb Company Company Information
  45. 8.8.2 Bristol-Myers Squibb Company Business Overview
  46. 8.8.3 Bristol-Myers Squibb Company T Cell Antigen Gp39 Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Bristol-Myers Squibb Company T Cell Antigen Gp39 Product Portfolio
  48. 8.8.5 Bristol-Myers Squibb Company Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 T Cell Antigen Gp39 Value Chain Analysis
  2. 9.1.1 T Cell Antigen Gp39 Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 T Cell Antigen Gp39 Sales Mode & Process
  6. 9.2 T Cell Antigen Gp39 Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 T Cell Antigen Gp39 Distributors
  9. 9.2.3 T Cell Antigen Gp39 Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst